The World Health Organization has urged the initiation of a full human trial for the Ervebo vaccine in the Democratic Republic of Congo to evaluate its potential against the Bundibugyo Ebola strain. This recommendation follows encouraging results from animal testing, suggesting that the vaccine may offer protection beyond the Zaire strain it was originally developed for. With the Bundibugyo strain causing recent outbreaks in DR Congo, health experts see the trial as a vital step in strengthening the response to this emerging threat. The study would focus on vaccinating high-risk individuals in affected regions while closely tracking safety and immune response.
Implementing the trial faces substantial challenges due to weak healthcare systems, ongoing violence, and difficulties in maintaining the required cold chain for vaccine storage. Gaining community trust remains critical, especially in areas where misinformation about vaccines is common. International organizations including Doctors Without Borders and local health authorities are collaborating with the WHO to address these issues. Their coordinated efforts aim to ensure the trial can proceed safely and effectively, potentially leading to broader use of the vaccine in future Ebola emergencies.